193 related articles for article (PubMed ID: 34970366)
1. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
Yanai H; Katsuyama H; Hakoshima M
Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
[TBL] [Abstract][Full Text] [Related]
2. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
3. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
[TBL] [Abstract][Full Text] [Related]
4. Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis.
Dohmen K; Onohara SY; Harada S
Korean J Gastroenterol; 2021 Oct; 78(4):227-234. PubMed ID: 34697277
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
[TBL] [Abstract][Full Text] [Related]
6. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.
Yamashita S; Rizzo M; Su TC; Masuda D
Metabolites; 2023 May; 13(5):. PubMed ID: 37233667
[TBL] [Abstract][Full Text] [Related]
7. Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice.
Iitake C; Iitake K
J Clin Med Res; 2019 Oct; 11(10):690-695. PubMed ID: 31636783
[TBL] [Abstract][Full Text] [Related]
8. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.
Yanai H; Katsuyama H; Hakoshima M
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203610
[TBL] [Abstract][Full Text] [Related]
9. Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.
Nishida M; Horio T; Fukuda Y; Hayakawa Y; Tateishi Y; Akai M; Emoto M; Hasegawa T; Imanishi M
Int J Clin Pharmacol Ther; 2023 Oct; 61(10):437-444. PubMed ID: 37548458
[TBL] [Abstract][Full Text] [Related]
10. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
Komatsu T; Miura T; Joko K; Sunohara D; Mochidome T; Kasai T; Ikeda U
Intern Med; 2021 Sep; 60(17):2741-2748. PubMed ID: 33776008
[TBL] [Abstract][Full Text] [Related]
11. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
12. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
Sairyo M; Kobayashi T; Masuda D; Kanno K; Zhu Y; Okada T; Koseki M; Ohama T; Nishida M; Sakata Y; Yamashita S
J Atheroscler Thromb; 2018 Feb; 25(2):142-152. PubMed ID: 28781340
[TBL] [Abstract][Full Text] [Related]
13. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
[TBL] [Abstract][Full Text] [Related]
16. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
Kito K; Nomoto H; Sakuma I; Nakamura A; Cho KY; Kameda H; Miya A; Omori K; Yanagiya S; Handa T; Taneda S; Takeuchi J; Nagai S; Yamashita K; Kurihara Y; Atsumi T; Miyoshi H;
Diabetes Res Clin Pract; 2022 Oct; 192():110091. PubMed ID: 36174777
[TBL] [Abstract][Full Text] [Related]
17. Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion.
Kitamura S; Murao N; Yokota S; Shimizu M; Ono T; Seino Y; Suzuki A; Maejima Y; Shimomura K
BMC Res Notes; 2023 Sep; 16(1):202. PubMed ID: 37697384
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review.
Khan MS; Ghumman GM; Baqi A; Shah J; Aziz M; Mir T; Tahir A; Katragadda S; Singh H; Taleb M; Ali SS
Am J Cardiovasc Drugs; 2023 Sep; 23(5):547-558. PubMed ID: 37524955
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.
Shima H; Tashiro M; Inoue T; Okada K; Okamoto T; Wariishi S; Doi T; Minakuchi J
Cureus; 2024 Apr; 16(4):e57777. PubMed ID: 38715994
[TBL] [Abstract][Full Text] [Related]
20. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
Fruchart JC; Hermans MP; Fruchart-Najib J
Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
